Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in c-MYC and HER2 amplified gastro-oesophageal carcinoma
2015-005525-39Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in Gastroesophageal carcinoma (GEC) and esophagogastric junction cancer, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Best overall response rate. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
Gastroesophageal carcinoma (GEC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2015-005525-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005525-39.